Depinar, a drug that potentially inhibits the binding and entry of COVID-19 into host cells based on computer-aided studies

Autor: Meysam Yazdani, Jafar Khezri, Nastaran Hadizadeh, Javad Zamani Amir Zakaria, Mousa Naderi, Sahar Mahmoodian, Ali Asghar Karkhanei, Farideh Razi, Mohammad Hossein Sanati, Ehsan Hashemi
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Research in Pharmaceutical Sciences, Vol 16, Iss 3, Pp 315-325 (2021)
Druh dokumentu: article
ISSN: 1735-5362
1735-9414
09461485
DOI: 10.4103/1735-5362.314830
Popis: Background and purpose: The new coronavirus (Covid-19) has resulted in great global concerns. Due to the mortality of this virus, scientists from all over the world have been trying to employ different strategies to tackle down this concern. This virus enters cells via phagocytosis through binding to the angiotensin-converting enzyme II receptor. After invading the body, it can stay hidden in there for a period of up to 24 days (incubation period). Experimental approach: In this report, by the use of in silico studies we selected several FDA-approved compounds that possess antiviral properties. We chose the viral Spike protein as the target of drug compounds and carried out the screening process for the FDA databank in order to find the most effective ligand. Findings/Results: The results from dock and MD revealed 10 compounds with high affinity to the receptor-binding domain motif of S protein. The best inhibitors were the ingredients of Depinar, which managed to effectively block the interactions between cells and virus. Conclusion and implication: The results of this study were approved by in silico studies and due to the lack of time; we did not test the efficiency of these compounds through in vitro and in vivo studies. However, the selected compounds are all FDA approved and some are supplements like vitamin B12 and don’t cause any side effects for patients.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje